{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-24-000026","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.099538+00:00","generated_at":"2026-05-31T14:09:05.853879+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD","bullets":["Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).","Dupixent global net sales up 27% to $3.56B; EU approved for COPD; FDA decision expected Sept 27, 2024.","EYLEA HD/EYLEA U.S. sales $1.53B (+2%), including $304M from EYLEA HD.","Libtayo global net sales up 42% to $297M; pipeline progress in obesity, gene therapy, oncology.","New $3B share repurchase authorization; $601M repurchased in Q2; 2024 guidance updated."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-24-000026","json":"https://secwatch.observer/filing/0001804220-24-000026.json","markdown":"https://secwatch.observer/filing/0001804220-24-000026.md","text":"https://secwatch.observer/filing/0001804220-24-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000026/0001804220-24-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000026/regn-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:09:05.853879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}